Answers are grounded in this paper and cite their sources.
Liver fibrosis is a dynamic and partially reversible pathological process driven by chronic liver injury, yet effective antifibrotic therapies remain limited. Astragaloside IV (AS-IV), a major bioactive constituent isolated from Astragalus mongholicus Bunge, exerts a broad range of pharmacological effects, including anti-inflammatory, antioxidant, and antifibrotic effects. This review synthesizes current evidence on the pharmacological characteristics, mechanistic basis, preclinical efficacy, and translational challenges of AS-IV in liver fibrosis. Available evidence indicates that AS-IV exerts its antifibrotic effects primarily by suppressing hepatic stellate cell activation, with modulation of transforming growth factor-β/Smad signaling representing the most consistently supported mechanism. Beyond this principal pathway, AS-IV may attenuate profibrotic amplification loops by enhancing antioxidant responses and suppressing inflammatory signaling, while also reducing upstream profibrotic stimuli through hepatoprotective effects. However, its clinical translation remains limited by poor oral bioavailability, inadequately defined pharmacokinetic-pharmacodynamic relationships, and a lack of high-quality clinical evidence. Overall, AS-IV represents a promising preclinical antifibrotic candidate, although clinical efficacy and pharmacological optimization remain to be established.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: